Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A. Mita MM, et al. Among authors: tolcher aw. Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74. doi: 10.1007/s00280-006-0255-0. Epub 2006 May 31. Cancer Chemother Pharmacol. 2007. PMID: 16736151 Clinical Trial.
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A. Guo F, et al. Among authors: tolcher aw. Cancer Chemother Pharmacol. 2008 Jun;62(1):97-109. doi: 10.1007/s00280-007-0579-4. Epub 2007 Sep 6. Cancer Chemother Pharmacol. 2008. PMID: 17805538 Clinical Trial.
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O'Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW. Lin CC, et al. Among authors: tolcher aw. Cancer Chemother Pharmacol. 2009 May;63(6):1065-71. doi: 10.1007/s00280-008-0811-x. Epub 2008 Sep 16. Cancer Chemother Pharmacol. 2009. PMID: 18795291 Clinical Trial.
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, De Bono JS, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A. Lin CC, et al. Among authors: tolcher aw. Cancer Chemother Pharmacol. 2009 Dec;65(1):167-75. doi: 10.1007/s00280-009-1020-y. Epub 2009 May 16. Cancer Chemother Pharmacol. 2009. PMID: 19449006 Clinical Trial.
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
Ricart AD, Ashton EA, Cooney MM, Sarantopoulos J, Brell JM, Feldman MA, Ruby KE, Matsuda K, Munsey MS, Medina G, Zambito A, Tolcher AW, Remick SC. Ricart AD, et al. Among authors: tolcher aw. Cancer Chemother Pharmacol. 2011 Oct;68(4):959-70. doi: 10.1007/s00280-011-1565-4. Epub 2011 Feb 9. Cancer Chemother Pharmacol. 2011. PMID: 21305290 Clinical Trial.
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A. Lush RM, et al. Cancer Chemother Pharmacol. 2012 Oct;70(4):567-74. doi: 10.1007/s00280-012-1942-7. Epub 2012 Aug 10. Cancer Chemother Pharmacol. 2012. PMID: 22878520 Free PMC article. Clinical Trial.
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ, Puchalski TA, Balkwill F, Berns B, Seetharam S, de Bono JS, Tolcher AW. Sandhu SK, et al. Among authors: tolcher aw. Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50. doi: 10.1007/s00280-013-2099-8. Epub 2013 Feb 6. Cancer Chemother Pharmacol. 2013. PMID: 23385782 Clinical Trial.
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder A. Patnaik A, et al. Among authors: tolcher aw. Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506. doi: 10.1007/s00280-013-2149-2. Epub 2013 Mar 30. Cancer Chemother Pharmacol. 2013. PMID: 23543270 Free PMC article. Clinical Trial.
206 results